Condition (MeSH)
Neuroleptic Malignant Syndrome
ClinicalTrials.gov lists 4 trials for Neuroleptic Malignant Syndrome or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
4 of the 4 trials are tagged with Neuroleptic Malignant Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Neuroleptic Malignant Syndrome trials start? (4)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2020 | 1 |
| 2010 | 1 |
| 2009 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Neuroleptic Malignant Syndrome trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 1 |
| Phase 2 | 1 |
| Observational | 2 |
How many Neuroleptic Malignant Syndrome trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Completed | 1 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Neuroleptic Malignant Syndrome trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Nerviano Medical Sciences (Shanghai) Ltd. | 1 |
| cerbomed GmbH | 1 |
Which publications cover Neuroleptic Malignant Syndrome? (6)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Molecular and immunological origins of catatonia. | Schizophrenia research | 2024 | Yes |
| Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study. | BMJ open | 2017 | Yes |
| Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. | Lancet (London, England) | 1998 | Yes |
| A rationale for NMDA receptor antagonist therapy of the neuroleptic malignant syndrome. | Medical hypotheses | 1992 | Yes |
| Relationship between bladder dysfunction and brain MRI in multiple sclerosis. | Functional neurology | 1991 | Yes |
Showing 5 of 6 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Neuroleptic malignant syndrome | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Neuroleptic malignant syndrome | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Neuroleptic malignant syndrome | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Neuroleptic malignant syndrome | 94093 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Neuroleptic malignant syndrome | 94093 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.